Cannabis as Medicine

The Pharmaceutical Journal Draft guidance says patients with chronic pain should not be offered tetrahydrocannabinol (THC) or mixtures of cannabidiol and THC unless the treatment is part of a clinical trial. The National Institute for Health and Care Excellence (NICE) has said it is currently unable to recommend cannabis-based medical products (CBMPs) for severe treatment-resistant epilepsy. In

Dr Robert L Dupont’s written Testimony to the FDA Regarding the Health Impacts of CBD

A researcher from the University of Houston has found that adults who take prescription opioids for severe pain are more likely to have increased anxiety, depression and substance abuse issues if they also use marijuana. Under the guidance of advisor Michael Zvolensky, Hugh Roy and Lillie Cranz Cullen Distinguished University Professor of psychology and director

Conclusions: Results of this study show that the frequency with which women in California use cannabis in the year before and during pregnancy has increased over time, corresponding with increasing acceptance of cannabis use and decreasing perceptions of cannabis-associated harms. Future studies are critically needed to determine whether and how the adverse outcomes of maternal perinatal

F.D.A. WARNING LETTER Challenging ‘Health Claims of CBD’ Curaleaf, Inc MARCS-CMS 579289 — JUL 22, 2019 This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address https://curaleafhemp.com External Link Disclaimer in April and June 2019 and has determined that you take orders there for the products “CBD

GW Pharmaceuticals has become the first firm to win European approval for a drug derived from the cannabis plant. Epidyolex treats patients, mostly children, who suffer from two severe forms of epilepsy: Lennox-Gastaut syndrome and Dravet syndrome. Sufferers can endure up to 74 full-blown “drop seizures” a month, in which they shake and fall down. The

JAMA Netw Open. 2019;2(7):e196471.  doi:10.1001/jamanetworkopen.2019.6471  Findings  In this serial cross-sectional study of 367 403 pregnancies among women in Kaiser Permanente Northern California who were universally screened for self-reported cannabis use as part of standard prenatal care, annual relative rates of daily, weekly, and monthly cannabis use in the year before pregnancy and during pregnancy increased from 2009 to

View Video

Professor Jennifer D. Thomas, co-director of the Center for Behavioral Teratology at San Diego State University who co-authored the rodent study told Newsweek: “Although it has been known that prenatal alcohol exposure can adversely affect later behavioral development, this study suggests that prenatal cannabis exposure can also influence behavioral development, and that effects may be more severe when

Today, a new study published in the journal Addiction found that living near a marijuana dispensary increases the likelihood of marijuana use and frequency of use among young people aged 18-22. “This study proves if you live near pot shops and their ads, you’re more likely to use marijuana,” said Dr. Kevin Sabet, president of Smart Approaches